TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gut Microbiome Study in Preterm Infants - a Norwegian Multi Centre Study
Brief Summary: Necrotizing enterocolitis (NEC) is a leading cause of morbidity and mortality among infants in the neonatal intensive care unit (NICU). It has been postulated that abnormal colonization of the preterm gut, or an unfavorable balance between gut bacteria may contribute to the development of NEC.

Recent clinical randomized studies and meta-analysis have shown that proactive colonization of probiotic bacteria reduce the frequency of NEC. Based on this evidence, in April 2014 all Norwegian NICUs started routinely administration of probiotics to all extremely premature neonates susceptible to NEC (gestational age \<28 weeks/birth weight \<1000g).

The current project is investigating the gut microbiome in patients receiving probiotics and compare the the gut microbiome with moderate premature infants not receiving probiotics. In addition, we are including a control of healthy full-term infants.

Samples containing feces from participants will be analyzed by state of the art whole-genome sequencing techniques. Bacterial diversity will be analysed with bioinformatic tools.

Study hypotheses:

* Probiotics given to extremely preterm infants will change the biodiversity of the gut microflora.
* Antibiotics given to these patients may influence the gut microflora also in infants receiving probiotics. In particular use of vancomycin may change the gut flora.
* After cessation of probiotic prophylaxis the gut flora of infants receiving probiotics will gradually resemble the gut flora of infants not receiving probiotics.
* A cross-contamination of probiotic bacteria between patients treated with probiotics and patients not treated with antibiotics may occur.


Options:
A: Arm Label: Probiotics; Type: N/A; Interventions: N/A
B: Arm Label: Bifidobacterium lactis plus inulin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Arm Label: maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis plus inulin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis plus inulin; Assigned to Arm(s): maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Bifidobacterium lactis plus inulin
C: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
D: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BiClamp Forceps Liver Transection Versus Clamp Crushing Technique in Liver Resections: A Randomized Clinical Trial
Brief Summary: The purpose of this study is to compare short-term and long-term efficacy of BiClamp forceps hepatectomy and clamp-crushing technique for parenchymal transection during elective hepatic resection.


Options:
A: Arm Label: Clamp-Crush technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clamp-Crush technique | Arm Label: Stapler hepatectomy; Type: EXPERIMENTAL; Interventions: Procedure: Stapler hepatectomy | Intervention Type: PROCEDURE; Name: Clamp-Crush technique; Assigned to Arm(s): Clamp-Crush technique | Intervention Type: PROCEDURE; Name: Stapler hepatectomy; Assigned to Arm(s): Stapler hepatectomy
B: Arm Label: Sangustop; Type: EXPERIMENTAL; Interventions: Device: Sangustop | Arm Label: Tachosil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tachosil | Intervention Type: DEVICE; Name: Sangustop; Assigned to Arm(s): Sangustop | Intervention Type: DRUG; Name: Tachosil; Assigned to Arm(s): Tachosil
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: rThrombin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: bovine thrombin | Intervention Type: BIOLOGICAL; Name: rThrombin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: bovine thrombin; Assigned to Arm(s): 2
D: Arm Label: Clamp-Crushing technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clamp-Crushing technique | Arm Label: BiClamp forceps hepatectomy; Type: EXPERIMENTAL; Interventions: Device: BiClamp forceps | Intervention Type: PROCEDURE; Name: Clamp-Crushing technique; Assigned to Arm(s): Clamp-Crushing technique | Intervention Type: DEVICE; Name: BiClamp forceps; Assigned to Arm(s): BiClamp forceps hepatectomy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D In the Prevention of Viral-induced Asthma of Preschoolers: a Randomised Controlled Trial (RCT)- (DIVA)
Brief Summary: In this 7-month randomized controlled trial, children aged 1-6 years with asthma attacks triggered mostly by colds, will receive a high dose of vitamin D or a placebo every 3.5 months during their usual clinic visit. This study will test whether children receiving a high dose of vitamin D have less frequent and less severe asthma exacerbations compared with those receiving placebo.The study will also document the safety profile of this strategy.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vigantol oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Miglyol oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Miglyol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Vigantol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Miglyol oil; Assigned to Arm(s): Miglyol oil
C: Arm Label: Ciclesonide + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: Ciclesonide + Vitamin D; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3, Drug: Ciclesonide | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Ciclesonide + Vitamin D | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide + Vitamin D, Ciclesonide + placebo
D: Arm Label: Vigantol oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Miglyol oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Miglyol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Vigantol oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Miglyol oil; Assigned to Arm(s): Miglyol oil

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D In the Prevention of Viral-induced Asthma of Preschoolers: a Randomised Controlled Trial (RCT)- (DIVA)
Brief Summary: In this 7-month randomized controlled trial, children aged 1-6 years with asthma attacks triggered mostly by colds, will receive a high dose of vitamin D or a placebo every 3.5 months during their usual clinic visit. This study will test whether children receiving a high dose of vitamin D have less frequent and less severe asthma exacerbations compared with those receiving placebo.The study will also document the safety profile of this strategy.


Options:
A: Arm Label: Oral Vitamin D--200 IU/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Oral Vitamin D--800 IU/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Oral Vitamin D--200 IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Oral Vitamin D--800 IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: RUTF with Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D, Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Arm Label: RUTF with Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): RUTF with Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Ready to Use Therapeutic Food (RUTF); Assigned to Arm(s): RUTF with Placebo, RUTF with Vitamin D
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin D | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing Frozen-thawed Embryo Transfer Treatment Cycles
Brief Summary: This is a randomised controlled trial on the effect of endometrial injury in the cycle preceding the frozen-thawed embryo transfer (FET) cycles. The study hypothesis is that endometrial injury will increase the ongoing pregnancy rate in FET cycles.


Options:
A: Arm Label: EA; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial biopsy | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: control procedure, Device: Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France) | Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): EA | Intervention Type: PROCEDURE; Name: control procedure; Assigned to Arm(s): Control | Intervention Type: DEVICE; Name: Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France); Assigned to Arm(s): Control
B: Arm Label: group 1 : IVF with biopsy; Type: EXPERIMENTAL; Interventions: Procedure: biopsy | Arm Label: group 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: IVF | Intervention Type: PROCEDURE; Name: biopsy; Assigned to Arm(s): group 1 : IVF with biopsy | Intervention Type: PROCEDURE; Name: IVF; Assigned to Arm(s): group 2
C: Arm Label: Endometrial Injury; Type: ACTIVE_COMPARATOR; Interventions: Other: Endometrial Injury | Arm Label: Luteal Phase Support; Type: ACTIVE_COMPARATOR; Interventions: Drug: progesterone (Crinone® %8 vaginal progesterone gel) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Endometrial Injury; Assigned to Arm(s): Endometrial Injury | Intervention Type: DRUG; Name: progesterone (Crinone® %8 vaginal progesterone gel); Assigned to Arm(s): Luteal Phase Support
D: Arm Label: Endometrial Biopsy; Type: EXPERIMENTAL; Interventions: Device: Endometrial Biopsy | Arm Label: Without Biopsy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Endometrial Biopsy; Assigned to Arm(s): Endometrial Biopsy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Domiciliary Physiotherapy During Breast Cancer Radiation
Brief Summary: Background: Breast cancer is the most common type of cancer among women. Its treatment, including radiotherapy (RT), can cause potential complications to be treated by the physiotherapy. Objective: To evaluate the effect of domiciliary physiotherapy on the upper limb applied during the period of radiotherapy in women submitted to surgical and radiotherapy for breast cancer. Study design: This is a prospective randomized controlled clinical trial. Methods: Thirty six volunteers were recruited from November 2009 to March 2012 and they were appraised at three different times: pre-RT, post-RT and 2 months after the end of RT. The parameters evaluated were: shoulder range of movement (ROM) and arm circumference. They were divided into two groups: CG) control group, submitted only to the assessments and SG) study group, submitted to domiciliary physiotherapy.


Options:
A: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Study Group; Type: EXPERIMENTAL; Interventions: Other: Domiciliary exercises for the upper limbs | Intervention Type: OTHER; Name: Domiciliary exercises for the upper limbs; Assigned to Arm(s): Study Group
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: Arm I (Control); Type: ACTIVE_COMPARATOR; Interventions: Other: questionnaire administration, Procedure: quality-of-life assessment, Procedure: management of therapy complications | Arm Label: Arm II (Exercise); Type: EXPERIMENTAL; Interventions: Other: questionnaire administration, Procedure: quality-of-life assessment, Procedure: management of therapy complications, Behavioral: exercise intervention | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): Arm I (Control), Arm II (Exercise) | Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): Arm II (Exercise)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Behavior Change | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Behavior Change; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Mobility-Enhancing Nursing Intervention in Patients With MS and Stroke: Randomised Controlled Trial
Brief Summary: Objectives: This parallel RCT investigated the effect of a new nursing intervention (Mobility Enhancing Nursing Intervention - MFP) designed to improve the rehabilitation programs' outcomes and patients' quality of life.

Intervention: The IG combined standard care with the 30-day mobility-enhancing-nursing intervention (MFP). MFP placed patients on a mattress on the floor and used constant tactile-kinaesthetic stimulation in everyday tasks to increase spatial orientation, to teach patients to get up safely and to move independently.

Primary and secondary outcome measures: Outcomes were defined as functionality (Extended Barthel Index, EBI), quality of life (WHOQoL), and fall-related self-efficacy (FES-I).


Options:
A: Arm Label: Higher-intensity RT group; Type: EXPERIMENTAL; Interventions: Device: RT, Behavioral: Conventional rehabilitation (CR) | Arm Label: Lower-intensity RT group; Type: EXPERIMENTAL; Interventions: Device: RT, Behavioral: Conventional rehabilitation (CR) | Arm Label: Conventional rehabilitation (CR) group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional rehabilitation (CR) | Intervention Type: DEVICE; Name: RT; Assigned to Arm(s): Higher-intensity RT group, Lower-intensity RT group | Intervention Type: BEHAVIORAL; Name: Conventional rehabilitation (CR); Assigned to Arm(s): Conventional rehabilitation (CR) group, Higher-intensity RT group, Lower-intensity RT group
B: Arm Label: Mobility-enhancing-nursing intervention; Type: EXPERIMENTAL; Interventions: Procedure: Mobility-enhancing-nursing intervention | Arm Label: Standard usual rehabilitation care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Mobility-enhancing-nursing intervention; Assigned to Arm(s): Mobility-enhancing-nursing intervention
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: functional rehabilitation nursing program | Arm Label: control group; Type: EXPERIMENTAL; Interventions: Other: control group | Intervention Type: OTHER; Name: functional rehabilitation nursing program; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: control group; Assigned to Arm(s): control group
D: Intervention Type: BEHAVIORAL; Name: Conventional UK Physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increased intensity of UK conventional physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: UK conventional physical therapy plus functional strength training; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)
Brief Summary: The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid arthritis (RA) randomized to an adalimumab dose tapering regimen controlled by adalimumab withdrawal.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Adalimumab Tapering; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Adalimumab Withdrawal Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Adalimumab 40 mg eow Rescue Arm; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg eow, Adalimumab 40 mg eow Rescue Arm, Adalimumab Tapering | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Adalimumab Withdrawal Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Usual Care Randomized Study Measuring the Impact of an Online Personal Health Record (Sanoia) in Rheumatoid Arthritis Patients on Reported Outcomes
Brief Summary: Recommendations of Rheumatoid Arthritis management agree on the necessity of patient self-involvement in the care. In parallel, the observation of the adoption rate of websites directed toward patients may indicate that this involvement is shared by a large number ot the population.

However, most of these sites are only informative and few of them offer patients to be engaged to generate their own data that can impact on the patient-physician relationship by easing the dialog and then leading to better mutual understanding.

As new web or mobile services allowing patients to self-report their outcomes are flourishing only a very few of them have already addressed the their impact of the patient-physician relationship.

The main objective of this study is to quantify the effect of a website (Sanoia) on the quality of patient-doctor interactions, as perceived by the patient using the french translations of the Peppi Questionnaire during the 12 months observation period.

In France, the patient protection committee (CPP) has ranked this study in "Soins Courants" (Usual Care).


Options:
A: Arm Label: PRO-based follow-up; Type: EXPERIMENTAL; Interventions: Behavioral: PRO-based follow-up | Arm Label: PRO-based telephone consultations; Type: EXPERIMENTAL; Interventions: Behavioral: PRO-based telephone consultation | Arm Label: Usual outpatient follow-up visits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PRO-based follow-up; Assigned to Arm(s): PRO-based follow-up | Intervention Type: BEHAVIORAL; Name: PRO-based telephone consultation; Assigned to Arm(s): PRO-based telephone consultations
B: Arm Label: HealthPROMISE users; Type: EXPERIMENTAL; Interventions: Other: HealthPROMISE users | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: HealthPROMISE users; Assigned to Arm(s): HealthPROMISE users | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
C: Arm Label: PHR Group; Type: ACTIVE_COMPARATOR; Interventions: Other: SANOIA Website | Arm Label: Non-PHR Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SANOIA Website; Assigned to Arm(s): PHR Group
D: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Behavioral: Baseline and Follow-up Surveys, Other: Patient Reported Outcome Measure informed Decision Aid | Arm Label: Non Treatment Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Baseline and Follow-up Surveys, Other: Pamphlet | Intervention Type: BEHAVIORAL; Name: Baseline and Follow-up Surveys; Assigned to Arm(s): Non Treatment Group, Treatment Group | Intervention Type: OTHER; Name: Patient Reported Outcome Measure informed Decision Aid; Assigned to Arm(s): Treatment Group | Intervention Type: OTHER; Name: Pamphlet; Assigned to Arm(s): Non Treatment Group

Answer: C